ATAI Life Sciences buys majority stake in NY-based Perception Neuroscience

January 3, 2019 Off By Dino Mustafić

ATAI Life Sciences AG has acquired a majority stake in New York based Perception Neuroscience, a biopharmaceutical company focused on developing innovative therapies in neuropsychiatry.

 

Co-investing with ATAI is New York-based investment firm Morgan Noble that specializes in transformative healthcare solutions, Subversive Capital that focuses on companies that require sophisticated government and regulatory strategies for success and life sciences investor WPSS Investments, ATAi said in a press release on Wednesday.

The buyer noted that Perception Neuroscience’s lead product is the NMDA antagonist arketamine (PCN 101), a single isomer of ketamine. Arketamine belongs to a new generation of glutamate receptor modulators with the potential for rapid acting antidepressant (RAAD) activity and anti-suicidal effects. These new RAAD drugs are expected to be more efficacious than current FDA-approved anti-depressant therapies, which often take weeks to achieve maximal effectiveness, if at all. Ketamine, as described in the journal Science “is arguably the most important discovery in half a century” of research in depression, and arketamine is anticipated to differentiate robustly from other development stage RAAD’s on both efficacy and safety.

ATAI CEO and co-founder Florian Brand said in the press release: “We are very excited about this investment, as arketamine is expected to have activity across a range of psychiatric conditions, including treatment resistant depression, bipolar depression, post-traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD) and substance abuse disorder. Perception will initiate its clinical trial program in early 2019, focusing initially on severe depression, because it is the leading cause of disability worldwide. In the US alone, the market for depression medication is expected to grow to USD 7.3 billion by 2024”.

Perception founders Jonathan Sporn and Jay Kranzler have been referred to comment: “We are gratified to have ATAI on board as an investor and partner, as we share their ambitious vision, admire their network of world-class scientists, and intend to leverage the synergies across their portfolio to significantly speed up the drug development process and maximize chances for success”.

Lars Christian Wilde, co-founder of COMPASS Pathways, another large ATAI investment added: “Arketamine has the potential to be very complementary to the psilocybin-based therapy that we are currently developing for treatment resistant depression, which recently received FDA breakthrough therapy designation.”